Rena Conti | Questrom School of Business Important Announcement2 December, 2020 at 1:14 PMVisit Back2BU for the latest updates and information on BU's response to COVID-19. Students can find additional information in the Undergraduate Student Guide and Graduate & Professional Student Guide. Questrom School of Business Creating Value for the World Hire Questrom Give Insights@Questrom Search Menu Search About Admissions Degree Programs Faculty & Research Executive Education Careers Student Life Alumni Parents & Families News Calendar Contact Us BOSTON UNIVERSITY Questrom School of Business Rafik B. Hariri Building 595 Commonwealth Avenue Boston, MA 02215 (617) 353-9720 Facebook Twitter YouTube Instagram LinkedIn Search Search for: Faculty Directory Home/Faculty & Research/Faculty Directory/Rena Conti Rena Conti Deans Research Scholar Associate Professor,Markets, Public Policy, and Law Associate Research Director, Institute for Health System Innovation and Policy Phone 617-353-1156 Email rconti@bu.edu Office 514B BOSTON UNIVERSITY Questrom School of Business Rafik B. Hariri Building 595 Commonwealth Avenue Boston, MA 02215 Download CV Publications Chua, K., Lee, J., Conti, R. (2020). "Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes", JAMA Internal Medicine, 180 (7), 1012-1012 Nikpay, S., Buntin, M., Conti, R. (2020). "Relationship between initiation of 340B participation and hospital safety-net engagement", Health Services Research, 55 (2), 157-169 Conti, R., Dusetzina, S., Sachs, R. (2020). "How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.", Health Aff (Millwood), 39 (3), 445-452 Chua, K., Brummett, C., Conti, R., Bohnert, A. (2020). "Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults", JAMA Pediatrics, 174 (2), 141-141 Chua, K., Schwartz, A., Volerman, A., Conti, R., Huang, E. (2020). "Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured Children", Pediatrics, 145 (2), e20192325-e20192325 Vermeulen, L., Swarthout, M., Alexander, G., Ginsburg, D., Pritchett, K., White, S., Tryon, J., Emmerich, C., Nesbit, T., Greene, W., Fox, E., Conti, R., Scott, B., Sheehy, F., Melby, M., Lantzy, M., Hoffman, J., Knoer, S., Zellmer, W. (2020). "ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems", American Journal of Health-System Pharmacy, 77 (2), 84-112 Woo, J., Anderson, B., Gruenstein, D., Conti, R., Chua, K. (2019). "Minimum Travel Distance Among Publicly Insured Infants with Severe Congenital Heart Disease: Potential Impact of In-state Restrictions.", Pediatr Cardiol, 40 (8), 1599-1608 Chen, A., Hu, X., Conti, R., Jena, A., Goldman, D. (2019). "Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017", Value in Health, 22 (12), 1387-1395 Conti, R., Berndt, E., Shivdasani, Y., Kaygisiz, N. (2019). "The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications", Conti, R. (2019). "Financial Toxicity of Prescription Drugs", Annals of Internal Medicine, 171 (9), 665-665 Conti, R., Berndt, E., Adajar, P. (2019). "The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration", Conti, R., Nikpay, S., Buntin, M. (2019). "Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016", JAMA Network Open, 2 (10), e1914141-e1914141 Conti, R., Berndt, E. (2019). "Four Facts Concerning Competition in US Generic Prescription Drug Markets", International Journal of the Economics of Business 1-22 Conti, R., Berndt, E. (2019). "Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets", Royce, T., Kircher, S., Conti, R. (2019). "Pharmacy Benefit Manager Reform", JAMA, 322 (4), 299-299 Chua, K., Brummett, C., Conti, R., Haffajee, R., Prosser, L., Bohnert, A. (2019). "Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids", JAMA Network Open, 2 (5), e193673-e193673 Chua, K., Conti, R. (2019). "Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014", Journal of General Internal Medicine, 34 (3), 338-340 GaBI Journal Editor, . (2018). "US generic prescription drug markets 20042016", Generics and Biosimilars Initiative Journal, 7 (4), 164-164 Conti, R., Nikpay, S., Buntin, M. (2018). "Diversity of Participants in the 340B Drug Pricing Program for US Hospitals", Journal of the American Medical Association Internal Medicine, 178 (8), 1124-1127 Conti, R., Nguyen, K., Rosenthal, M. (2018). "Generic Prescription Drug Price Increases: Which Products Will Be Affected by Proposed Anti-Gouging Legislation", Journal of Pharmaceutical Policy and Practice, 11 (1), 29-29 Conti, R., Chua, K. (2018). "Out-of-Pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014", Journal of General Internal Medicine, 178 (4), 133-140 Parsons, S., Lerner, D., Rodday, A., Curtis, R., Kelly, K., Conti, R., Castellino, S., Henderson, T. (2018). "Parental work limitations at diagnosis of advanced stage pediatric Hodgkin lymphomaResults of caregiver work limitations questionnaire (CG WLQ).", Journal of Clinical Oncology, 36 (15_suppl), e18927-e18927 Berndt, E., Conti, R., Murphy, S. (2018). "The generic drug user fee amendments: an economic perspective", Journal of Law and the Biosciences, 5 (1), 103-141 Conti, R., Berndt, E. (2018). Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 20012007. In David, Cutler. (Eds.), "Measuring and Modeling Health Care Costs Advances in CRIW Conference Proceedings", University of Chicago Press Conti, R., Chua, K., Shrime, M. (2017). "Effect of FDA Investigation on Opioid Prescribing to Children after Tonsillectomy/Adenoidectomy", Pediatrics, 140 (6), 6-6 Dusetzina, S., Conti, R., Yu, N., Bach, P. (2017). "Association of Prescription Drug Price Rebates in Medicare Part D with Patient Out-of-Pocket and Federal Spending", Journal of the American Medical Association Internal Medicine, 177 (8), 1185-1188 Conti, R. (2017). "Biosimilars: Reimbursement Issues in Your Oncology Practice", Journal of Oncology Practice, 13 (9), 12-14 Conti, R., DeSouza, J. (2017). "Mitigating Financial Toxicity among US Patients with Cancer", Journal of the American Medical Association Oncology, 3 (6), 765-766 Conti, R. (2017). "Biosimilars: Reimbursement Issues in Your Oncology Practice", Journal of Oncology Practice, 13 (9_suppl), 12s-14s Conti, R., Berndt, E. (2017). "The Generic Drug User Fee Amendments: An Economic Perspective", Conti, R., Murphy, S., Berndt, E. (2017). "The Landscape of US Generic Prescription Drug Markets, 20042016", The National Bureau of Economic Research Conti, R., Chua, K. (2017). "Out-of-Pocket Spending among Commercially Insured Patients for Epinephrine Autoinjectors between 2007 and 2014", Journal of the American Medical Association Internal Medicine, 176 (2), 736-739 Chua, K., Conti, R. (2017). "Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014", JAMA Internal Medicine, 177 (5), 736-736 Conti, R., Jones, D. (2017). "Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA", Journal of Health Politics, Policy and Law, 42 (2), 377-385 Chua, K., Conti, R., Freed, G. (2017). "Appropriately Framing Child Health Care Spending: A Prerequisite for Value Improvement", Conti, R., padula, w. (2017). Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the U.S. and the E.U.. In Richard, Hehlmann. (Eds.), "Chronic Myeloid Leukemia: What Every Clinical Practitioner Needs to Know in 2017", ASCO Henderson, T., Castellino, S., Keller, F., Kelly, K., Curtis, R., Conti, R., Parsons, S. (2016). "Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents", Blood, 128 (22), 3583-3583 Chua, K., Schwartz, A., Volerman, A., Conti, R., Huang, E. (2016). "Use of Low-Value Pediatric Services Among the Commercially Insured", PEDIATRICS, 138 (6), e20161809-e20161809 Conti, R., Gee, R., Sharfstein, J. (2016). "Pharmaceuticals and Public Health", JAMA, 316 (20), 2083-2083 Pitts, P., Louet, H., Moride, Y., Conti, R. (2016). "21st century pharmacovigilance: efforts, roles, and responsibilities", The Lancet Oncology, 17 (11), e486-e492 Conti, R. (2016). "The Advantages of Awarding the Federal Government Negotiating Power Over the Prices of Prescription Drugs", Journal of Policy Analysis and Management, 35 (4), 964-970 Conti, R. (2016). "Response to Joyce and Sood", Journal of Policy Analysis and Management, 35 (4), 972-974 Padula, W., Larson, R., Dusetzina, S., Apperley, J., Hehlmann, R., Baccarani, M., Eigendorff, E., Guilhot, J., Guilhot, F., Hehlmann, R., Mahon, F., Martinelli, G., Mayer, J., Mller, M., Niederwieser, D., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Conti, R. (2016). "Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States", Journal of the National Cancer Institute, 108 (7), djw003-djw003 Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2016). "A Pathway Through the Bundle Jungle", Journal of Oncology Practice, 12 (6), 504-509 Clark, B., Hou, J., Huang, E., Conti, R., Chou, C. (2016). "Medication Adherence among Hiv/Aids Patients Receiving 340b-Purchased Antiretroviral Medications", Value in Health, 19 (3), A8-A8 Weiner, A., Conti, R., Eggener, S. (2016). "National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions", Journal of Urology, 195 (5), 1383-1389 Bach, P., Conti, R., Muller, R., Schnorr, G., Saltz, L. (2016). "Overspending driven by oversized single dose vials of cancer drugs", BMJ i788-i788 Conti, R., Rosenthal, M. (2016). "Pharmaceutical Policy Reform Balancing Affordability with Incentives for Innovation", New England Journal of Medicine, 374 (8), 703-706 Dusetzina, S., Ellis, S., Freedman, R., Conti, R., Winn, A., Chambers, J., Alexander, G., Huskamp, H., Keating, N. (2015). "How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab", Journal of Oncology Practice, 11 (4), 313-318 Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2015). "Reply to M. Thompson et al", Journal of Oncology Practice, 11 (3), 263-264 Polite, B., Conti, R., Ward, J. (2015). "Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist", American Society of Clinical Oncology Educational Book (35), e75-e80 Padula, W., Larson, R., Conti, R., Dusetzina, S. (2015). "Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis", Value in Health, 18 (3), A205-A205 Conti, R., Padula, W., Larson, R. (2015). "Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU", Annals of Hematology, 94 (S2), 249-257 Howard, D., Bach, P., Berndt, E., Conti, R. (2015). "Pricing in the Market for Anticancer Drugs", Journal of Economic Perspectives, 29 (1), 139-162 Gibbons, R., Coca Perraillon, M., Hur, K., Conti, R., Valuck, R., Brent, D. (2015). "Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents", Pharmacoepidemiology and Drug Safety, 24 (2), 208-214 Conti, R. (2015). "Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change", Journal of Oncology Practice, 11 (1), e95-e97 Larson, R., Conti, R., Padula, W., Apperley, J., Baccarani, M., Eigendorff, E., Guilhot, F., Guilhot, J., Mahon, F., Martinelli, G., Mayer, J., Mueller, M., Niederwieser, D., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Hehlmann, R. (2014). "What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?", Blood, 124 (21), 738-738 Padula, W., Conti, R., Larson, R. (2014). "What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?", Value in Health, 17 (7), A636-A636 Conti, R., Bach, P. (2014). "Improving Outpatient Oncology Practice: Several Steps Into a Long Journey", Journal of Oncology Practice, 10 (6), 355-356 Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2014). "Payment for Oncolytics in the United States: A History of Buy and Bill and Proposals for Reform", Journal of Oncology Practice, 10 (6), 357-362 Clark, B., Hou, J., Chou, C., Huang, E., Conti, R. (2014). "The 340B Discount Program: Outpatient Prescription Dispensing Patterns Through Contract Pharmacies In 2012", Health Affairs, 33 (11), 2012-2017 Conti, R., Bach, P. (2014). "The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities", Health Affairs, 33 (10), 1786-1792 Conti, R., Fein, A., Bhatta, S. (2014). "National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011", Health Affairs, 33 (10), 1721-1727 Howard, D., Conti, R. (2014). "Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013.", Journal of Clinical Oncology, 32 (15_suppl), 6525-6525 Goldberg, P., Conti, R. (2014). "Problems With Public Reporting of Cancer Quality Outcomes Data", Journal of Oncology Practice, 10 (3), 215-218 Conti, R. (2013). "Drug Discount ProgramReply", JAMA, 310 (15), 1627-1627 Conti, R., Dusetzina, S., Herbert, A., Berndt, E., Huskamp, H., Keating, N. (2013). "The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs", Medical Care, 51 (7), 622-627 Conti, R., Bach, P. (2013). "Cost Consequences of the 340B Drug Discount Program", JAMA, 309 (19), 1995-1995 Kornfield, R., Watson, S., Higashi, A., Conti, R., Dusetzina, S., Garfield, C., Dorsey, E., Huskamp, H., Alexander, G. (2013). "Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 20042008", Psychiatric Services, 64 (4), 339-346 Conti, R., Bernstein, A., Villaflor, V., Schilsky, R., Rosenthal, M., Bach, P. (2013). "Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists", Journal of Clinical Oncology, 31 (9), 1134-1139 Dusetzina, S., Busch, A., Conti, R., Donohue, J., Caleb Alexander, G., Huskamp, H. (2012). "Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory", Pharmacoepidemiology and Drug Safety, 21 (12), 1251-1260 Dusetzina, S., Higashi, A., Dorsey, E., Conti, R., Huskamp, H., Zhu, S., Garfield, C., Alexander, G. (2012). "Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors", Medical Care, 50 (6), 466-478 Conti, R., Rosenthal, M., Polite, B., Bach, P., Shih, Y. (2012). "Infused Chemotherapy Use in the Elderly After Patent Expiration", Journal of Oncology Practice, 8 (3S), e18s-e23s Philipson, T., Eber, M., Lakdawalla, D., Corral, M., Conti, R., Goldman, D. (2012). "An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is Worth It In The Case Of Cancer", Health Affairs, 31 (4), 667-675 Garfield, C., Dorsey, E., Zhu, S., Huskamp, H., Conti, R., Dusetzina, S., Higashi, A., Perrin, J., Kornfield, R., Alexander, G. (2012). "Trends in Attention Deficit Hyperactivity Disorder Ambulatory Diagnosis and Medical Treatment in the United States, 20002010", Academic Pediatrics, 12 (2), 110-116 Pillarella, J., Higashi, A., Alexander, G., Conti, R. (2012). "Trends in Use of Second-Generation Antipsychotics for Treatment of Bipolar Disorder in the United States, 19982009", Psychiatric Services, 63 (1), 83-86 Conti, R. (2011). "Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005", Psychiatric Services, 62 (7), 720-720 Conti, R., Busch, A., Cutler, D. (2011). "Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005", Psychiatric Services, 62 (7), 720-726 Meltzer, D., Basu, A., Conti, R. (2010). "The Economics of Comparative Effectiveness Studies", PharmacoEconomics, 28 (10), 843-853 Qato, D., Lindau, S., Conti, R., Schumm, L., Alexander, G. (2010). "Racial and ethnic disparities in cardiovascular medication use among older adults in the United States", Pharmacoepidemiology and Drug Safety, 19 (8), 834-842 Conti, R., Veenstra, D., Armstrong, K., Lesko, L., Grosse, S. (2010). "Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities", Medical Decision Making, 30 (3), 328-340 Conti, R. (2010). "Advances in economics to further inform investments in vaccine development", Human Vaccines, 6 (4), 286-291 Qato, D., Lindau, S., Conti, R., Alexander, G. (2009). "PIH51 Racial/Ethnic Disparities in Prescription Drug Use Among Older Adults in the United States", Value in Health, 12 (3), A171-A171 (2008). "Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United States", JAMA, 300 (24), 2867-2867 Conti, R., Meltzer, D., Ratain, M. (2008). "Nonprofit Biomedical Companies", Clinical Pharmacology & Therapeutics, 84 (2), 194-197 Rosenthal, M., Landrum, M., Meara, E., Huskamp, H., Conti, R., Keating, N. (2007). "Using Performance Data to Identify Preferred Hospitals", Health Services Research, 42 (6p1), 2109-2119 Chien, A., Conti, R., Pollack, H. (2007). "A pediatric-focused review of the performance incentive literature", Current Opinion in Pediatrics, 19 (6), 719-725 Frank, R., Conti, R., Goldman, H. (2005). "Mental Health Policy and Psychotropic Drugs", The Milbank Quarterly, 83 (2), 271-298 Rebitzer, J., Frandsen, B., Powell, M., Conti, R. (2019). "Common Agent or Double Agent? An Economic Model of Pharmacy Benefit Management", BOSTON UNIVERSITY Questrom School of Business Rafik B. Hariri Building 595 Commonwealth Avenue Boston, MA 02215 (617) 353-9720 Facebook Twitter YouTube Instagram LinkedIn
